Literature DB >> 9115750

Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids.

M Nauck1, M Roth, M Tamm, O Eickelberg, H Wieland, P Stulz, A P Perruchoud.   

Abstract

Vascular endothelial growth factor (VEGF) is a potent peptide growth factor specific for vascular endothelial cells, which promotes neovascularization and increases vascular permeability in vivo. Enhanced microvascular permeability and edema are common characteristics of inflammatory and neoplastic disorders. Two proinflammatory mediators, platelet-activating factor (PAF) and platelet-derived growth factor (PDGF), are known to contribute to cellular damage and tissue remodeling in a number of lung diseases. To determine whether PAF or PDGF induce VEGF gene expression in primary cultures of human pulmonary fibroblasts and pulmonary vascular smooth-muscle cells (VSMCs), we performed Northern-blot analysis and enzyme-linked immunosorbent assays (EIA). PAF and all three isoforms of PDGF (PDGF-AA, -AB, and -BB) increased VEGF mRNA in a time- and dose-dependent manner. While PAF was shown to increase VEGF mRNA at picomolar concentrations, all PDGF isoforms were effective in inducing VEGF mRNA at nanomolar concentrations. The transcriptional activation was accompanied by increased levels of VEGF protein as determined by EIA in culture medium. These results indicate that VEGF gene expression in VSMCs and fibroblasts is mediated by PAF and/or PDGF isoforms. In a paracrine mode of action, secreted VEGF may then lead to altered endothelial cell functions and vascular hyperpermeability. In the presence of the corticosteroids cortisone, hydrocortisone, dexamethasone, or prednisolone at nanomolar concentrations, this stimulus-dependent transcription of VEGF was abolished. The inhibitory effect of corticosteroids on VEGF expression could explain the clinically well-known antiedematous potency of corticosteroids on a molecular level.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9115750     DOI: 10.1165/ajrcmb.16.4.9115750

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  47 in total

1.  Treatment of recurrent retinal angiomatous proliferation with intravitreal triamcinolone acetonide followed by photodynamic therapy with verteporfin: A retrospective case series.

Authors:  Nicola Cardascia; Claudio Furino; Andrea Ferrara; Francesco Boscia; Giovanni Alessio
Journal:  Curr Ther Res Clin Exp       Date:  2009-06

2.  mRNA differential display identification of vascular smooth muscle early response genes regulated by PDGF.

Authors:  Joe O Minta; James J Yun; Oluyomi Kabiawu; Jabbal Jones
Journal:  Mol Cell Biochem       Date:  2006-01       Impact factor: 3.396

3.  Intravitreal injection of bevacizumab and triamcinolone acetonide at the end of vitrectomy for diabetic vitreous hemorrhage: a comparative study.

Authors:  Dong Ho Park; Jae Pil Shin; Si Yeol Kim
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-12-12       Impact factor: 3.117

4.  Bevacizumab versus triamcinolone for persistent diabetic macular edema: a randomized clinical trial.

Authors:  Murilo W Rodrigues; José A Cardillo; André Messias; Rubens C Siqueira; Ingrid U Scott; Rodrigo Jorge
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-12-23       Impact factor: 3.117

5.  Vascularity in asthmatic airways: relation to inhaled steroid dose.

Authors:  B E Orsida; X Li; B Hickey; F Thien; J W Wilson; E H Walters
Journal:  Thorax       Date:  1999-04       Impact factor: 9.139

6.  Effect of posterior sub-tenon triamcinolone in macular edema due to non-ischemic vein occlusions.

Authors:  Murali Mohan Gurram
Journal:  J Clin Diagn Res       Date:  2013-09-13

7.  A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema.

Authors: 
Journal:  Ophthalmology       Date:  2008-07-26       Impact factor: 12.079

8.  Intravitreal Diclofenac plus Bevacizumab versus Bevacizumab alone in treatment-naive diabetic macular edema: a randomized double-blind clinical trial.

Authors:  Heshmatollah Ghanbari; Farzan Kianersi; Seyed Ali Sonbolestan; Mohammad-Ali Abtahi; Mojataba Akbari; Zahra-Alsadat Abtahi; Seyed-Hossein Abtahi
Journal:  Int Ophthalmol       Date:  2016-09-13       Impact factor: 2.031

9.  Involvement of vascular endothelial growth factor in exercise induced bronchoconstriction in asthmatic patients.

Authors:  H Kanazawa; K Hirata; J Yoshikawa
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

10.  Combined application of 17beta-estradiol and progesterone enhance vascular endothelial growth factor and surfactant protein expression in cultured embryonic lung cells of mice.

Authors:  Andreas Trotter; Markus Kipp; Roland Matthias Schrader; Cordian Beyer
Journal:  Int J Pediatr       Date:  2009-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.